Fiprokil Spot On Solution 50 mg for Cats

Main information

  • Trade name:
  • FIPROKIL SOLUTION POUR SPOT ON POUR CHAT
  • Pharmaceutical form:
  • Spot-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FIPROKIL SOLUTION POUR SPOT ON POUR CHAT
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • fipronil
  • Therapeutic area:
  • Cats

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0468/001
  • Authorization date:
  • 20-03-2013
  • EU code:
  • UK/V/0468/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:September2013

AN:00681/2012

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

BobMartinClear50mgspot-onsolutionforcats

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

One0.5mlpipettecontains:

Activesubstance:

Fipronil 50mg

Excipients:

ButylhydroxyanisoleE320 0.1mg

ButylhydroxytolueneE321 0.05mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Spot-onsolution.

Clear,paleambersolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Cats.

4.2 Indicationsforuse,specifyingthetargetspecies

Treatmentofflea(Ctenocephalidesspp.)infestations.

Fleaswillbekilledwithin24h.Theproducthasapersistentinsecticidalefficacyfor

upto5weeksagainstfleas(Ctenocephalidesspp.).

Althoughnoimmediatekillingeffectagainsttickshasbeendemonstrated,the

producthasshownanacaricidalefficacyagainstDermacentorreticulatus.Ifticksof

thisspeciesarepresentwhentheproductisapplied,alltheticksmaynotbekilled

withinthefirst48hoursbuttheywillbekilledwithinaweek.

4.3 Contraindications

Donotuseonkittenslessthan2monthsoldand/orweighinglessthan1kg.

Donotuseonsick(systemicdiseases,fever…)orconvalescentanimals.

Donotuseinrabbits,asadversedrugreactionsandevendeathcouldoccur.

Revised:September2013

AN:00681/2012

Donotuseonanimalswithknownhypersensitivitytotheactivesubstanceortoany

ofexcipients.

4.4Specialwarningsforeachtargetspecies

Fleasfrompetsofteninfesttheanimal'sbasket,beddingandregularrestingareas

suchascarpetsandsoftfurnishingswhichshouldbetreated,incaseofmassive

infestationandatthebeginningofthecontrolmeasures,withasuitableinsecticide

andvacuumedregularly.

Avoidfrequentswimmingorshampooingtheanimalbecausethemaintenanceof

effectivenessoftheproductinthesecaseshasnotbeentested.

Foroptimumcontroloffleaproblemsinamulti-pethousehold,alldogsandcatsin

thehouseholdshouldbetreatedwithasuitableinsecticide.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Avoidcontactwiththeanimal’seyes.Inthecaseofaccidentaleyecontact,

immediatelyandthoroughlyflushtheeyeswithwater.

Donotapplytheproductonwoundsordamagedskin.

Itisimportanttomakesurethattheproductisappliedtoanareawheretheanimal

cannotlickitoff,andtomakesurethatanimalsdonotlickeachotherfollowing

treatment.

Specificstudiesincatsinvestigatingthesafetyoftheproductfollowingrepeated

administrationoratover-dosagehavenotbeenconductedduetotheknownsafety

profileoftheactivesubstancesandexcipients.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Thisproductcancausemucousmembraneandeyeirritation.Therefore,contact

betweentheproductandthemouthoreyesshouldbeavoided.

Inthecaseofaccidentaleyecontact,immediatelyandthoroughlyflushtheeyeswith

water.Ifeyeirritationpersistsseekmedicaladviceandshowthepackageleafletor

thelabeltothephysician.

Avoidcontentscomingintocontactwiththefingers.Ifthisoccurs,washhandswith

soapandwater.Washhandsafteruse.

Donotsmoke,drinkoreatduringapplication.

Animalsorpeoplewithaknownhypersensitivitytofiproniloranyoftheother

ingredientsshouldavoidcontactwiththeproduct.Treatedanimalsshouldnotbe

handleduntiltheapplicationsiteisdry,andchildrenshouldnotbeallowedtoplay

withtreatedanimalsuntiltheapplicationsiteisdry.Itisthereforerecommendedthat

animalsarenottreatedduringtheday,butshouldbetreatedduringtheearly

evening,andthatrecentlytreatedanimalsshouldnotbeallowedtosleepwith

owners,especiallychildren.

Revised:September2013

AN:00681/2012

Otherprecautions

Theproductmayhaveadverseeffectsonpainted,varnishedorotherhousehold

surfacesorfurnishings.

4.6Adversereactions(frequencyandseriousness)

Iflickingoccurs,abriefperiodofhypersalivationmaybeobservedduemainlytothe

natureofthecarrier.

Amongtheextremelyraresuspectedadversereactions,transientcutaneous

reactionsattheapplicationsite(squamosis,localalopecia,pruritus,erythema)and

generalpruritusoralopeciahavebeenreportedafteruse.Exceptionally,

hypersalivation,reversibleneurologicsymptoms(hyperesthesia,depression,nervous

symptoms)orvomitinghavebeenobservedafteruse.

4.7Useduringpregnancy,lactationorlay

Laboratorystudiesusingfipronilhavenotshownanyevidenceofteratogenicor

embryotoxiceffects.Studieshavenotbeencarriedoutwiththisproductinpregnant

andlactatingqueens.Useinpregnancyandlactationonlyinaccordancewith

professionalveterinaryadviceandabenefit/riskassessment.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9 Amountstobeadministeredandadministrationroute

Routeofadministrationanddosage:

Externaluseonly.

Administerbytopicalapplicationtotheskin1pipetteof0.5mlperanimal.

Removethepipettefromtheblisterpackaging.Holdthepipetteinanuprightposition

andsnapoffthetopsectionofthecap,therebyopeningthepipette.

Partthepet’scoatuntiltheskinisvisible.Placethetipofthetubedirectlyagainstthe

baredskinandsqueezegently.Emptyapproximatelyhalfthecontentsateachoftwo

pointsalongthecat’sback.Thefirstapplicationpointisatthebaseoftheheadand

Revised:September2013

AN:00681/2012

thesecondapplicationpointisbetweentheshoulderblades.Squeezethetube

severaltimestoensuredosingiscomplete.Avoidapplyingthesolutionontothefur

anddonotrubintotheskin.

Applicationofthesolutionasdirectedminimisesthepossibilitythattheanimalwilllick

thesolutionoff.

Careshouldbetakentoavoidexcessivewettingofthehairwiththeproductsince

thiswillcauseastickyappearanceofhairsatthetreatmentspot.However,should

thisoccur,itwillusuallydisappearwithin24-48hourspostapplication.Crystalsmay

beseenonthehairandslightscalingmayoccurwithin24-48hoursafterapplication.

Treatmentschedule:

Foroptimalcontroloffleainfestationthetreatmentschedulecanbebasedonthe

localepidemiologicalsituation.

Theminimumintervalbetweentwotreatmentsis4weeks.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Thetoxicityoftheveterinarymedicinalproductwhenadministeredtotheskinisvery

low.Theriskofexperiencingadverseeffects(seesection4.6)mayincreaseincases

ofover-dose,soanimalsshouldalwaysbetreatedwiththecorrectproductaccording

tospeciesandbodyweight.

Noadverseeffectswereobservedinatargetanimalsafetystudyineightweeks-old

catsweighingabout1kgtreatedwith5timesthetherapeuticdosemonthlyforthree

months.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Ectoparasiticidesfortopicaluse.

ATCvetcode:QP53AX15

5.1 Pharmacodynamicproperties

Fipronilisaninsecticideandacaricidebelongingtothephenylpyrazolefamily.Itacts

byinhibitingtheGABAcomplex,bindingtothechloridechannelandtherebyblocking

pre-andpost-synaptictransferofchlorideionsacrosscellmembranes.Thisresults

inuncontrolledactivityofthecentralnervoussystemanddeathofinsectsoracarids.

Fipronilexhibitsaninsecticidalandacaricidalactivityagainstfleas(Ctenocephalides

spp)andacaricidalactivityagainstticks(Dermacentorreticulatus)inthecat.

Revised:September2013

AN:00681/2012

5.2Pharmacokineticparticulars

Invitro,fipronilismainlymetabolisedwithsubcellularliverfractionstoitssulfone

derivative.However,thismaybeoflimitedrelevance‘invivo’asfipronilispoorly

absorbedinthecat.Theconcentrationsoffipronilonthehairdecreasewithtime.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

ButylhydroxyanisoleE320

ButylhydroxytolueneE321

Benzylalcohol

Diethyleneglycolmonoethylether

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years.

6.4.Specialprecautionsforstorage

Storebelow25°C,inadryplaceintheoriginalpackaging.

6.5Natureandcompositionofimmediatepackaging

Whiteopaqueorpinkorgreentranslucentpolypropylenesingle-dosepipettescontaining

anextractablevolumeof0.5mlpackagedinaclearPVCblisterclosedbyheatsealing

withaluminiumfoilandplacedinacartonboxorblistercard.

Blistercardsorboxesof1,2,3,4,5or6pipettes.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Fipronilmayadverselyaffectaquaticorganisms.Donotcontaminateponds,waterways

orditcheswiththeproductoremptycontainer.

Revised:September2013

AN:00681/2012

7. MARKETINGAUTHORISATIONHOLDER

BobMartinUKLtd.

WemberhamLane

Yatton

Somerset

BS494BS

UK

8. MARKETINGAUTHORISATIONNUMBER

Vm00715/4119

9. DATEOFFIRSTAUTHORISATION

Date:14December2011

10. DATEOFREVISIONOFTHETEXT

Date:September2013

APPROVED 20/09/13

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

19-11-2018

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

One lot each of Option Family Sunscreen Lotion SPF 50 and Personnelle Sport Sunscreen Lotion SPF 50 have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination.

Health Canada

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration